Abstract
Background: No short patient-reported outcome (PRO) instruments assess overall health status across different obstructive lung diseases. Thus, the wording of the introduction to the Chronic Obstructive Pulmonary Disease (COPD) Assessment Test (CAT) was modified to permit use in asthma and/or COPD. This tool is called the Chronic Airways Assessment Test (CAAT). Methods: The psychometric properties of the CAAT were evaluated using baseline data from the NOVELTY study (NCT02760329) in patients with physician-assigned asthma, asthma + COPD or COPD. Analyses included exploratory/confirmatory factor analyses, differential item functioning and analysis of construct validity. Responses to the CAAT and CAT were compared in patients with asthma + COPD and those with COPD. Results: CAAT items were internally consistent (Cronbach’s alpha: > 0.7) within each diagnostic group (n = 510). Models for structural and measurement invariance were strong. Tests of differential item functioning showed small differences between asthma and COPD in individual items, but these were not consistent in direction and had minimal overall impact on the total score. The CAAT and CAT were highly consistent when assessed in all NOVELTY patients who completed both (N = 277, Pearson’s correlation coefficient: 0.90). Like the CAT itself, CAAT scores correlated moderately (0.4–0.7) to strongly (> 0.7) with other PRO measures and weakly (< 0.4) with spirometry measures. Conclusions: CAAT scores appear to reflect the same health impairment across asthma and COPD, making the CAAT an appropriate PRO instrument for patients with asthma and/or COPD. Its brevity makes it suitable for use in clinical studies and routine clinical practice. Trial registration: NCT02760329.
Original language | English |
---|---|
Article number | 106 |
Journal | Respiratory Research |
Volume | 24 |
Issue number | 1 |
DOIs | |
State | Published - 1 Dec 2023 |
Keywords
- Asthma
- COPD
- COPD Assessment Test
- Chronic Airways Assessment Test
- Patient-reported
- Psychometrics
Access to Document
Fingerprint
Dive into the research topics of 'Chronic Airways Assessment Test: psychometric properties in patients with asthma and/or COPD'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Respiratory Research, Vol. 24, No. 1, 106, 01.12.2023.
Research output: Contribution to journal › Article › peer-review
TY - JOUR
T1 - Chronic Airways Assessment Test
T2 - psychometric properties in patients with asthma and/or COPD
AU - for the NOVELTY Scientific Community
AU - and the NOVELTY study investigators
AU - Tomaszewski, Erin L.
AU - Atkinson, Mark J.
AU - Janson, Christer
AU - Karlsson, Niklas
AU - Make, Barry
AU - Price, David
AU - Reddel, Helen K.
AU - Vogelmeier, Claus F.
AU - Müllerová, Hana
AU - Jones, Paul W.
AU - del Olmo, Ricardo
AU - Anderson, Gary
AU - Rabahi, Marcelo
AU - McIvor, Andrew
AU - Sadatsafavi, Mohsen
AU - Weinreich, Ulla
AU - Burgel, Pierre Régis
AU - Devouassoux, Gilles
AU - Papi, Alberto
AU - Inoue, Hiromasa
AU - Rendon, Adrian
AU - van den Berge, Maarten
AU - Beasley, Richard
AU - García-Navarro, Alvar Agustí
AU - Faner, Rosa
AU - Rivera, José Olaguibel
AU - Janson, Christer
AU - Bilińska-Izydorczyk, Magdalena
AU - Fagerås, Malin
AU - Fihn-Wikander, Titti
AU - Franzén, Stefan
AU - Keen, Christina
AU - Ostridge, Kristoffer
AU - Chalmers, James
AU - Harrison, Timothy
AU - Pavord, Ian
AU - Price, David
AU - Azim, Adnan
AU - Belton, Laura
AU - Blé, Francois Xavier
AU - Erhard, Clement
AU - Gairy, Kerry
AU - Hughes, Rod
AU - Lassi, Glenda
AU - Müllerová, Hana
AU - Rapsomaniki, Eleni
AU - Scott, Ian Christopher
AU - Chipps, Bradley
AU - Make, Barry
AU - Cho, Young Joo
N1 - Funding Information: The authors would like to thank the patients who participated in this study and wish to acknowledge the work of the NOVELTY Scientific Community and the NOVELTY study investigators, who are listed in full below, and Sharon MacLachlan (Evidera, London, UK), who participated in the analysis of sections of the data. Medical writing support, under the direction of the authors, was provided by Niall Tyrer, MBiolSci, CMC Connect, a division of IPG Health Medical Communications, funded by AstraZeneca, Cambridge, UK, in accordance with Good Publication Practice (GPP 2022) guidelines (Ann Intern Med 2022; 175(9):1298–1304). Funding Information: The authors would like to thank the patients who participated in this study and wish to acknowledge the work of the NOVELTY Scientific Community and the NOVELTY study investigators, who are listed in full below, and Sharon MacLachlan (Evidera, London, UK), who participated in the analysis of sections of the data. Medical writing support, under the direction of the authors, was provided by Niall Tyrer, MBiolSci, CMC Connect, a division of IPG Health Medical Communications, funded by AstraZeneca, Cambridge, UK, in accordance with Good Publication Practice (GPP 2022) guidelines (Ann Intern Med 2022; 175(9):1298–1304). NOVELTY Scientific Community members: Ricardo del Olmo (Argentina), Gary Anderson (Australia), Helen Reddel (Australia), Marcelo Rabahi (Brazil), Andrew McIvor (Canada), Mohsen Sadatsafavi (Canada), Ulla Weinreich (Denmark), Pierre-Régis Burgel (France), Gilles Devouassoux (France), Alberto Papi (Italy), Hiromasa Inoue (Japan), Adrian Rendon (Mexico), Maarten van den Berge (Netherlands), Richard Beasley (New Zealand), Alvar Agustí García-Navarro (Spain), Rosa Faner (Spain), José Olaguibel Rivera (Spain), Christer Janson (Sweden), Magdalena Bilińska-Izydorczyk (AstraZeneca, Sweden), Malin Fagerås (AstraZeneca, Sweden), Titti Fihn-Wikander (AstraZeneca, Sweden), Stefan Franzén (AstraZeneca, Sweden), Christina Keen (AstraZeneca, Sweden), Kristoffer Ostridge (AstraZeneca, Sweden), James Chalmers (UK), Timothy Harrison (UK), Ian Pavord (UK), David Price (UK), Adnan Azim (AstraZeneca, UK), Laura Belton (AstraZeneca, UK), Francois-Xavier Blé (AstraZeneca, UK), Clement Erhard (AstraZeneca, UK), Kerry Gairy (AstraZeneca, UK), Rod Hughes (AstraZeneca, UK), Glenda Lassi (AstraZeneca, UK), Hana Müllerová (AstraZeneca, UK), Eleni Rapsomaniki (AstraZeneca, UK), Ian Christopher Scott (AstraZeneca, UK), Bradley Chipps (USA), Barry Make (USA), Stephanie Christenson (USA), Erin Tomaszewski (AstraZeneca, USA). NOVELTY study investigator collaborators: Argentina: Ricardo del Olmo (National Principal Investigator), Gabriel Benhabib, Xavier Bocca Ruiz, Raul Eduardo Lisanti, Gustavo Marino, Walter Mattarucco, Juan Nogueira, Maria Parody, Pablo Pascale, Pablo Rodriguez, Damian Silva, Graciela Svetliza, Carlos F. Victorio, Roxana Willigs Rolon, Anahi Yañez. Australia: Helen Reddel (National Principal Investigator), Stuart Baines, Simon Bowler, Peter Bremner, Sheetal Bull, Patrick Carroll, Mariam Chaalan, Claude Farah, Gary Hammerschlag, Kerry Hancock, Zinta Harrington, Gregory Katsoulotos, Joshua Kim, David Langton, Donald Lee, Matthew Peters, Lakshman Prassad, Dimitar Sajkov, Francis Santiago, Frederick Graham Simpson, Sze Tai, Paul Thomas, Peter Wark. Brazil: Marcelo Rabahi (National Principal Investigator), José Eduardo Delfini Cançado, Thúlio Cunha, Marina Lima, Alexandre Pinto Cardoso. Canada: J. Mark FitzGerald (National Principal Investigator), Andrew McIvor (National Principal Investigator), Syed Anees, John Bertley, Alan Bell, Amarjit Cheema, Guy Chouinard, Michael Csanadi, Anil Dhar, Ripple Dhillon, David Kanawaty, Allan Kelly, William Killorn, Daniel Landry, Robert Luton, Piushkumar Mandhane, Bonavuth Pek, Robert Petrella, Daniel Stollery. China: Chen Wang (National Principal Investigator), Meihua Chen, Yan Chen, Wei Gu, Kim Ming, Christopher Hui, Manxiang Li, Shiyue Li, Ma Lijun, Guangyue Qin, Weidong Song, Wei Tan, Yijun Tang, Tan Wang, Fuqiang Wen, Feng Wu, Ping Chao Xiang, Zuke Xiao, Shengdao Xiong, Jinghua Yang, Jingping Yang, Caiqing Zhang, Min Zhang, Ping Zhang, Wei Zhang, Xiaohe Zheng, Dan Zhu. Columbia: Carlos Matiz Bueno (National Principal Investigator), Fabio Bolivar Grimaldos, Alejandra Cañas Arboleda, Dora Molina de Salazar. Denmark: Ulla Weinreich (National Principal Investigator), Elisabeth Bendstrup, Ole Hilberg, Carsten Kjellerup. France: Pierre-Régis Burgel (National Principal Investigator), Gilles Devouassoux (National Principal Investigator), Chantal Raherison (National Principal Investigator), Philippe Bonniaud, Olivier Brun, Christos Chouaid, Francis Couturaud, Jacques de Blic, Didier Debieuvre, Dominique Delsart, Axelle Demaegdt, Pascal Demoly, Antoine Deschildre, Carole Egron, Lionel Falchero, François Goupil, Romain Kessler, Pascal Le Roux, Pascal Mabire, Guillaume Mahay, Stéphanie Martinez, Boris Melloni, Laurent Moreau, Emilie Riviere, Pauline Roux-Claudé, Michel Soulier, Guillaume Vignal, Azzedine Yaici. Germany: Robert Bals (National Principal Investigator), Sven Philip Aries, Ekkehard Beck, Andreas Deimling, Jan Feimer, Vera Grimm-Sachs, Gesine Growth, Felix Herth, Gerhard Hoheisel, Frank Kanniess, Thomas Lienert, Silke Mronga, Jörg Reinhardt, Christian Schlenska, Christoph Stolpe, Ishak Teber, Hartmut Timmermann, Thomas Ulrich, Peter Velling, Sabina Wehgartner-Winkler, Juergen Welling, Ernst-Joachim Winkelmann. Italy: Alberto Papi (National Principal Investigator), Carlo Barbetta, Fulvio Braido, Vittorio Cardaci, Enrico Maria Clini, Maria Teresa Costantino, Giuseppina Cuttitta, Mario di Gioacchino, Alessandro Fois, Maria Pia Foschino-Barbaro, Enrico Gammeri, Riccardo Inchingolo, Federico Lavorini, Antonio Molino, Eleonora Nucera, Vincenzo Patella, Alberto Pesci, Fabio Ricciardolo, Paola Rogliani, Riccardo Sarzani, Carlo Vancheri, Rigoletta Vincenti. Japan: Hiromasa Inoue (National Principal Investigator), Takeo Endo, Masaki Fujita, Yu Hara, Takahiko Horiguchi, Keita Hosoi, Yumiko Ide, Minehiko Inomata, Koji Inoue, Sumito Inoue, Motokazu Kato, Masayuki Kawasaki, Tomotaka Kawayama, Toshiyuki Kita, Kanako Kobayashi, Hiroshi Koto, Koichi Nishi, Junpei Saito, Yasuo Shimizu, Toshihiro Shirai, Naruhiko Sugihara, Ken-ichi Takahashi, Hiroyuki Tashimo, Keisuke Tomii, Takashi Yamada, Masaru Yanai. Mexico: Adrian Rendon (National Principal Investigator), Ruth Cerino Javier, Alfredo Domínguez Peregrina, Marco Fernández Corzo, Efraín Montano Gonzalez, Alejandra Ramírez-Venegas. Netherlands: Maarten van den Berge (National Principal Investigator), Willem Boersma, R.S. Djamin, Michiel Eijsvogel, Frits Franssen, Martijn Goosens, Lidwien Graat-Verboom, Johannes in 't Veen, Rob Janssen, Kim Kuppens, Mario van de Ven. Norway: Per Bakke (National Principal Investigator), Ole Petter Brunstad, Gunnar Einvik, Kristian Jong Høines, Alamdar Khusrawi, Torbjorn Oien. South Korea: Ho Joo Yoon (National Principal Investigator), Yoon-Seok Chang, Young Joo Cho, Yong Il Hwang, Woo Jin Kim, Young-Il Koh, Byung-Jae Lee, Kwan-Ho Lee, Sang-Pyo Lee, Yong Chul Lee, Seong Yong Lim, Kyung Hun Min, Yeon-Mok Oh, Choon-Sik Park, Hae-Sim Park, Heung-Woo Park, Chin Kook Rhee, Hyoung-Kyu Yoon. Spain: Alvar Agustí García-Navarro (National Principal Investigator), José Olaguibel Rivera (National Principal Investigator), Rubén Andújar, Laura Anoro, María Buendía García, Paloma Campo Mozo, Sergio Campos, Francisco Casas Maldonado, Manuel Castilla Martínez, Carolina Cisneros Serrano, Lorena Comeche Casanova, Dolores Corbacho, Felix Del Campo Matías, Jose Echave-Sustaeta, Gloria Francisco Corral, Pedro Gamboa Setién, Marta García Clemente, Ignacio García Núñez, Jose García Robaina, Mercedes García Salmones, Jose Maria Marín Trigo, Marta Nuñez Fernandez, Sara Nuñez Palomo, Luis Pérez de Llano, Ana Pueyo Bastida, Ana Rañó, José Rodríguez González-Moro, Albert Roger Reig, José Velasco Garrido. Sweden: Christer Janson (National Principal Investigator), Dan Curiac, Cornelia Lif-Tiberg, Anders Luts, Lennart Råhlen, Stefan Rustscheff. UK: Timothy Harrison (National Principal Investigator), Frances Adams, Drew Bradman, Emma Broughton, John Cosgrove, Patrick Flood-Page, Elizabeth Fuller, David Hartley, Keith Hattotuwa, Gareth Jones, Keir Lewis, Lorcan McGarvey, Alyn Morice, Preeti Pandya, Manish Patel, Kay Roy, Ramamurthy Sathyamurthy, Swaminathan Thiagarajan, Alice Turner, Jorgen Vestbo, Wisia Wedzicha, Tom Wilkinson, Pete Wilson. USA: Bradley Chipps (National Principal Investigator), Lo’Ay Al-Asadi, James Anholm, Francis Averill, Sandeep Bansal, Alan Baptist, Colin Campbell, Michael A. Campos, Gretchen Crook, Samuel DeLeon, Alain Eid, Ellen Epstein, Stephen Fritz, Hoadley Harris, Mitzie Hewitt, Fernando Holguin, Golda Hudes, Richard Jackson, Alan Kaufman, David Kaufman, Ari Klapholz, Harshavardhan Krishna, Daria Lee, Robert Lin, Diego Maselli-Caceres, Vinay Mehta, James N. Moy, Ugo Nwokoro, Purvi Parikh, Sudhir Parikh, Frank Perrino, James Ruhlmann, Catherine Sassoon, Russell A. Settipane, Daniel Sousa, Peruvemba Sriram, Richard Wachs Publisher Copyright: © 2023, The Author(s).
PY - 2023/12/1
Y1 - 2023/12/1
N2 - Background: No short patient-reported outcome (PRO) instruments assess overall health status across different obstructive lung diseases. Thus, the wording of the introduction to the Chronic Obstructive Pulmonary Disease (COPD) Assessment Test (CAT) was modified to permit use in asthma and/or COPD. This tool is called the Chronic Airways Assessment Test (CAAT). Methods: The psychometric properties of the CAAT were evaluated using baseline data from the NOVELTY study (NCT02760329) in patients with physician-assigned asthma, asthma + COPD or COPD. Analyses included exploratory/confirmatory factor analyses, differential item functioning and analysis of construct validity. Responses to the CAAT and CAT were compared in patients with asthma + COPD and those with COPD. Results: CAAT items were internally consistent (Cronbach’s alpha: > 0.7) within each diagnostic group (n = 510). Models for structural and measurement invariance were strong. Tests of differential item functioning showed small differences between asthma and COPD in individual items, but these were not consistent in direction and had minimal overall impact on the total score. The CAAT and CAT were highly consistent when assessed in all NOVELTY patients who completed both (N = 277, Pearson’s correlation coefficient: 0.90). Like the CAT itself, CAAT scores correlated moderately (0.4–0.7) to strongly (> 0.7) with other PRO measures and weakly (< 0.4) with spirometry measures. Conclusions: CAAT scores appear to reflect the same health impairment across asthma and COPD, making the CAAT an appropriate PRO instrument for patients with asthma and/or COPD. Its brevity makes it suitable for use in clinical studies and routine clinical practice. Trial registration: NCT02760329.
AB - Background: No short patient-reported outcome (PRO) instruments assess overall health status across different obstructive lung diseases. Thus, the wording of the introduction to the Chronic Obstructive Pulmonary Disease (COPD) Assessment Test (CAT) was modified to permit use in asthma and/or COPD. This tool is called the Chronic Airways Assessment Test (CAAT). Methods: The psychometric properties of the CAAT were evaluated using baseline data from the NOVELTY study (NCT02760329) in patients with physician-assigned asthma, asthma + COPD or COPD. Analyses included exploratory/confirmatory factor analyses, differential item functioning and analysis of construct validity. Responses to the CAAT and CAT were compared in patients with asthma + COPD and those with COPD. Results: CAAT items were internally consistent (Cronbach’s alpha: > 0.7) within each diagnostic group (n = 510). Models for structural and measurement invariance were strong. Tests of differential item functioning showed small differences between asthma and COPD in individual items, but these were not consistent in direction and had minimal overall impact on the total score. The CAAT and CAT were highly consistent when assessed in all NOVELTY patients who completed both (N = 277, Pearson’s correlation coefficient: 0.90). Like the CAT itself, CAAT scores correlated moderately (0.4–0.7) to strongly (> 0.7) with other PRO measures and weakly (< 0.4) with spirometry measures. Conclusions: CAAT scores appear to reflect the same health impairment across asthma and COPD, making the CAAT an appropriate PRO instrument for patients with asthma and/or COPD. Its brevity makes it suitable for use in clinical studies and routine clinical practice. Trial registration: NCT02760329.
KW - Asthma
KW - COPD
KW - COPD Assessment Test
KW - Chronic Airways Assessment Test
KW - Patient-reported
KW - Psychometrics
UR - http://www.scopus.com/inward/record.url?scp=85152065101&partnerID=8YFLogxK
U2 - 10.1186/s12931-023-02394-6
DO - 10.1186/s12931-023-02394-6
M3 - Article
C2 - 37031164
AN - SCOPUS:85152065101
SN - 1465-9921
VL - 24
JO - Respiratory Research
JF - Respiratory Research
IS - 1
M1 - 106
ER -